Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311480
Status:
COMPLETED
Last Update Posted:
2007-03-13
First Post:
2006-04-04
Brief Title:
Safety and Immunogenicity of Two Doses Administered Three Weeks Apart of TwoSurface Antigen Adjuvanted With MF59C1 Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase II Randomized Controlled Observer-Blind Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses Administered Three Weeks Apart of Two Surface Antigen Adjuvanted With MF59C1 Influenza Vaccines Containing 75 mg or 15 mg of H5N1 Influenza Antigen in Non-Elderly Adult and Elderly Subjects
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study aims to evaluate safety and immunogenicity of two doses administered three weeks apart of two influenza vaccines containing 75 micrograms or 15 micrograms of H5N1 influenza antigen in non-elderly adult and elderly subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract2005-005871-14 | None | None | None |